# Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis

> **NCT00450645** · PHASE4 · UNKNOWN · sponsor: **Azienda Ospedaliera Universitaria Policlinico** · enrollment: 300 (estimated)

## Conditions studied

- Deep Vein Thrombosis
- Cancer

## Interventions

- **DRUG:** low molecular weight heparin

## Key facts

- **NCT ID:** NCT00450645
- **Lead sponsor:** Azienda Ospedaliera Universitaria Policlinico
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-03
- **Primary completion:** 2009-03
- **Final completion:** 2011-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2009-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450645, "Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00450645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*